Advent-Morro Equity Partners

Ole Insurance Group focuses on offering protection and well-being products and services through technology. Ole Insurance Group was founded in 2021 and was headquartered in Puerto Rico.

Kiwi is a financial technology company founded in 2020 and based in San Juan, Puerto Rico. It offers an application aimed at promoting financial inclusion by providing users with access to affordable capital. The app facilitates quick account creation with rapid identity verification and allows users to report their loan payment behavior to major credit bureaus. This functionality helps users build their credit scores, enabling them to obtain unsecured loans and credit builder loans. Additionally, Kiwi focuses on enhancing financial literacy, making it a valuable resource for individuals seeking to improve their financial well-being.

Hyperion is an all-in-one finance app that integrates essential financial services for small businesses through a mobile application. Hyperion’s customers can validate a business in minutes, having access to cash management, B2B payments, financial reports, and a business network they can tap into.

Kiwi is a financial technology company founded in 2020 and based in San Juan, Puerto Rico. It offers an application aimed at promoting financial inclusion by providing users with access to affordable capital. The app facilitates quick account creation with rapid identity verification and allows users to report their loan payment behavior to major credit bureaus. This functionality helps users build their credit scores, enabling them to obtain unsecured loans and credit builder loans. Additionally, Kiwi focuses on enhancing financial literacy, making it a valuable resource for individuals seeking to improve their financial well-being.

Quench USA, Inc. specializes in Water-as-a-Service solutions, providing bottleless filtered water coolers and various related products, including ice machines and coffee brewers, throughout the United States. The company focuses on point-of-use systems that purify existing water supplies, delivering reliable and convenient filtered water to a diverse range of sectors, such as government, education, healthcare, manufacturing, retail, and hospitality, with a notable presence among Fortune 500 companies. Headquartered near Philadelphia, Quench employs advanced filtration technologies, including carbon filtration, reverse osmosis, and UV sanitization, to ensure the removal of contaminants and deliver clean, great-tasting water. By eliminating the need for bulky plastic jugs, Quench aims to reduce the environmental impact associated with traditional water delivery methods.

Quench USA, Inc. specializes in Water-as-a-Service solutions, providing bottleless filtered water coolers and various related products, including ice machines and coffee brewers, throughout the United States. The company focuses on point-of-use systems that purify existing water supplies, delivering reliable and convenient filtered water to a diverse range of sectors, such as government, education, healthcare, manufacturing, retail, and hospitality, with a notable presence among Fortune 500 companies. Headquartered near Philadelphia, Quench employs advanced filtration technologies, including carbon filtration, reverse osmosis, and UV sanitization, to ensure the removal of contaminants and deliver clean, great-tasting water. By eliminating the need for bulky plastic jugs, Quench aims to reduce the environmental impact associated with traditional water delivery methods.

Seven Seas Water Corporation is a multinational company specializing in outsourced water treatment, wastewater treatment, and reuse solutions for a diverse range of clients, including governmental, municipal, industrial, property developers, and hospitality sectors. Founded in 1996 and headquartered in Tampa, Florida, the company operates over 150 water and wastewater treatment plants across the United States, Caribbean, and Latin America. Seven Seas Water offers a comprehensive Water-as-a-Service model that includes custom desalination, advanced water treatment, and emergency water supplies. The firm is involved in both the development of new treatment facilities and the acquisition of existing operations, showcasing its capabilities in project execution and risk management. Through advanced technologies like seawater reverse osmosis, Seven Seas Water aims to provide cost-effective and sustainable water solutions, ensuring a reliable supply of potable and industrial process water for its clients.

AquaVenture Holdings is a water purification company headquartered in Tampa, Florida, that specializes in providing water solutions through its Quench and Seven Seas Water businesses. Established in 2006, the company offers water-as-a-service primarily in the British Virgin Islands, delivering reliable and cost-effective sources of clean drinking water and process water. AquaVenture Holdings employs advanced purification and desalination technologies to ensure safe water access for its clients, helping to protect families from unsafe drinking water and inadequate sanitation.

Bioheart, Inc. is dedicated to advancing the field of regenerative medicine by offering the highest quality technology, cellular treatments and training. Specific to biotechnology, Bioheart, Inc. specializes in the discovery, development and commercialization of autologous cellular therapies that treat a wide variety of degenerative diseases. Bioheart, Inc. is committed to maintaining its leading position within the cardiovascular sector of the cell technology industry by delivering stem cell therapies and biologics that help address congestive heart failure, lower limb ischemia, chronic heart ischemia, acute myocardial infarctions, chronic and acute heart damage, peripheral vascular disease and other issues. Bioheart's goals are to improve a patient’s quality of life by regenerating their damaged tissue, when possible, and by reducing health care costs and hospitalizations. Bioheart’s leading product, MyoCell, is a clinical muscle-derived cell therapy designed to populate regions of scar tissue within a patient's heart with new living cells for the purpose of improving cardiac function in chronic heart failure patients.